End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
33.73 CNY | -1.32% | -2.29% | +0.15% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.52 times its estimated earnings per share for the ongoing year.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.15% | 2.35B | - | ||
-3.15% | 89.69B | A- | ||
+3.95% | 41.34B | A- | ||
-10.51% | 33.72B | B- | ||
+60.65% | 26.11B | A | ||
-20.09% | 14.63B | C | ||
-8.92% | 12.84B | B- | ||
-11.46% | 11.66B | D+ | ||
-43.05% | 11.52B | B | ||
+3.97% | 8.92B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300294 Stock
- Ratings China Resources Boya Bio-pharmaceutical Group Co.,Ltd